Safety of topical tacrolimus: an update

( views:293, downloads:0 )
Author:
WANG Rui-hua(Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China)
ZHANG Tang-de(Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China)
Journal Title:
International Journal of Dermatology and Venereology
Issue:
Volume 38, Issue 02, 2012
DOI:
10.3760/cma.j.issn.1673-4173.2012.02.005
Key Word:
Tacrolimus;Safety;Administration, topical

Abstract: Tacrolimus is a macrolide immunosuppressant.The action mechanisms of tacrolimus are similar to that of cyclosporine.Since the molecular weight is low,tacrolimus can penetrate the epidermal barrier.Topical tacrolimus shows favorable efficacy in the treatment of atopic dermatitis and other T cellmediated dermatoses,and has been regarded as a new treatment alternative for skin diseases.The safety of long-term use of tacrolimus has attracted more and more attention because of its severe immunosuppressive effects and some potential problems of systemic absorption.Data are limited on the systemic evaluation of adverse reactions of topical tacrolimus.The authors review recent reports on side effects of topical tacrolimus at home and abroad,in hope to promote its proper use.

  • [1]Ring J,M(o)hrenschlager M,Henkel V,et al.The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.Drug Saf,2008,31 (3):185-198.
  • [2]Becker JC,Houben R,Vetter CS,et al.The carcinogenic potential of tacrolimus ointment beyond immune suppression:a hypothesis creating case report.BMC Cancer,2006,6:7.
  • [3]Mattsson U,Magnusson B,Jontell M.Squamous cell carcinoma in a patient with oral lichen planus treated with topical application of tacrolimus.Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2010,110(1):e19-e25.
  • [4]yon Felbert V,Hampl M,Talhari C,et al.Squamous cell carcinoma arising from a localized vulval lesion of Hailey-Hailey disease after tacrolimus therapy.Am J Obstet Gynecol,2010,203(3):e5-e7.
  • [5]Mikhail M,Wolchok J,Goldberg SM,et al.Rapid enlargement of a malignant melanoma in a child with vitiligo vulgaris after application of topical tacrolimus.Arch Dermatol,2008,144(4):560-561.
  • [6]Niwa Y,Terashima T,Sumi H.Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin.Br J Dermatol,2003,149(5):960-967.
  • [7]Tennis P,Gelfand JM,Rothman KJ.Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors.Br J Dermatol,2011,165 (3):465-473.
  • [8]Kimata H.Kapos's varicellifonn eruption associated with the use of tacrolimus ointment in two neonates. Indian J Dermatol Venereol Leprol,2008,74(3):262-263.
  • [9]Lübbe J,Pournaras CC,Saurat JH.Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment.Dermatology,2000,201 (3):249-251.
  • [10]Ambo M.Relapsing Kaposi's varicelliform eruption and herpes simplex following facial tacrolimus treatment for atopic dermatitis.Acta Derm Venereol,2002,82 (3):224-225.
  • [11]Osawa K,Etoh T,Ariyoshi N,et al.Relationship between Kaposi's varicelliform eruption in Japanese patients with atopic dermatitis treated with tacrolimus ointment and genetic polymorphisms in the IL-18 gene promoter region.J Dermatol,2007,34(8):531-536.
  • [12]Bilenchi R,Poggiali S,De Padova LA,et al.Human papillomavirus reactivation following topical tacrolimus therapy of anogenital lichen sclerosus.Br J Dermatol,2007,156 (2):405-406.
  • [13]Patrizi A,Neri I,Bianchi F,et al.Facial eruption of viral warts in a child treated with 0.03% tacrolimus ointment for atopic dermatitis.Pediatr Dermatol,2007,24(4):445-447.
  • [14]Mandelin J,Remitz A,Virtanen H,et al.One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis:A randomized,double-blind,comparative trial.Acta Derm Venereol,2010,90(2):170-174.
  • [15]Harper J,Smith C,Rubins A,et al.A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis.J Invest Dermatol,2005,124(4):695-699.
  • [16]Reitamo S,Wollenberg A,Schopf E,et al.Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis.The European Tacrolimus Ointment Study Group..Arch Dermatol,2000,136(8):999-1006.
  • [17]Hultsch T,Kapp A,Spergel J.Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Dermatology,2005,211 (2):174-187.
  • [18]B(o)hm M,Frieling U,Luger TA,et al.Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol,2003,139(7):922-924.
  • [19]Allen A,Siegfried E,Silverman R,et al.Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome.Arch Dermatol,2001,137(6):747-750.
  • [20]Weiss HM, Fresneau M,Moenius T,et al. Binding of pimecrolimus and tacrolimus to skin and plasma proteins:implications for systemic exposure after topical application.Drug Metab Dispos,2008,36(9):1812-1818.
  • [21]Ekberg H,Bernasconi C,N(o)ldeke J,et al.Cyclosporine,tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant,2010,25(6):2004-2010.
  • [22]Naesens M,Kuypers DR,Sarwal M.et al.Calcineurin inhibitor nephrotoxicity.Clin J Am Soc Nephrol,2009,4(2):481-508.
  • [23]史天陆,孙言才,沈爱宗,等.他克莫司临床不良反应与防治.中国医院用药评价与分析,2009,9(1):67.
  • [24]McCollum AD,Paik A,Eichenfield LF.The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis.Pediatr Dermatol,2010,27 (5):425-436.
  • [25]Elias PM.An Appropriate Response to the Black-Box Warning:Corrective,Barrier Repair Therapy in Atopic Dermatitis.Clin Med Dermatol,2009,2:1-3.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn